224 related articles for article (PubMed ID: 31478993)
1. Alterations in NKG2A and NKG2C Subsets of Natural Killer Cells Following Epstein-Barr Virus Reactivation in CTLA4Ig-based Haploidentical Transplantation Is Associated With Increased Chronic Graft-Versus-Host Disease.
Jaiswal SR; Bhakuni P; Bhagwati G; Aiyar HM; Chakrabarti A; Chakrabarti S
Transplantation; 2020 Jan; 104(1):e23-e30. PubMed ID: 31478993
[TBL] [Abstract][Full Text] [Related]
2. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
3. Early and Sustained Expansion of Adaptive Natural Killer Cells Following Haploidentical Transplantation and CTLA4Ig-Primed Donor Lymphocyte Infusions Dissociate Graft-versus-Leukemia and Graft-versus-Host Effects.
Jaiswal SR; Chakraborty S; Lakhchaura R; Shashi P; Mehta A; Soni M; Chakrabarti S
Transplant Cell Ther; 2021 Feb; 27(2):144-151. PubMed ID: 33830023
[TBL] [Abstract][Full Text] [Related]
4. Characterization of IFNγ-producing natural killer cells induced by cytomegalovirus reactivation after haploidentical hematopoietic stem cell transplantation.
Jin F; Lin H; Gao S; Wang H; Yan H; Guo J; Hu Z; Jin C; Wang Y; Wang Z; Zhao Y; Liu Y; Zheng X; Tan Y; Li W; Dai Y; Yang Y
Oncotarget; 2017 Jan; 8(1):51-63. PubMed ID: 27980216
[TBL] [Abstract][Full Text] [Related]
5. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
6. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
Front Immunol; 2020; 11():620891. PubMed ID: 33664733
[TBL] [Abstract][Full Text] [Related]
7. Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival.
Auger S; Orsini M; Céballos P; Fegueux N; Kanouni T; Caumes B; Klein B; Villalba M; Rossi JF
Eur J Haematol; 2014; 92(5):421-8. PubMed ID: 24400833
[TBL] [Abstract][Full Text] [Related]
8. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
Kheav VD; Busson M; Scieux C; Peffault de Latour R; Maki G; Haas P; Mazeron MC; Carmagnat M; Masson E; Xhaard A; Robin M; Ribaud P; Dulphy N; Loiseau P; Charron D; Socié G; Toubert A; Moins-Teisserenc H
Haematologica; 2014 Dec; 99(12):1860-7. PubMed ID: 25085354
[TBL] [Abstract][Full Text] [Related]
9. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
[TBL] [Abstract][Full Text] [Related]
10. Early Cytomegalovirus Reactivation and Expansion of CD56
Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.
Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980
[TBL] [Abstract][Full Text] [Related]
12. Virus reactivation and low dose of CD34+ cell, rather than haploidentical transplantation, were associated with secondary poor graft function within the first 100 days after allogeneic stem cell transplantation.
Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yan CH; Liu ZY; Huang XJ
Ann Hematol; 2019 Aug; 98(8):1877-1883. PubMed ID: 31144019
[TBL] [Abstract][Full Text] [Related]
13. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
[TBL] [Abstract][Full Text] [Related]
14. Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation.
Jaiswal SR; Singhal P; Thatai A; Bhagwati G; Aiyer HM; Chakrabarti A; Chakrabarti S
Ann Hematol; 2020 Apr; 99(4):839-845. PubMed ID: 32025839
[TBL] [Abstract][Full Text] [Related]
15. CTLA4Ig in an Extended Schedule along with Sirolimus Improves Outcome with a Distinct Pattern of Immune Reconstitution Following Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation for Hemoglobinopathies.
Jaiswal SR; Bhakuni P; Aiyer HM; Soni M; Bansal S; Chakrabarti S
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1469-1476. PubMed ID: 32428732
[TBL] [Abstract][Full Text] [Related]
16. CTLA4Ig Primed Donor Lymphocyte Infusion: A Novel Approach to Immunotherapy after Haploidentical Transplantation for Advanced Leukemia.
Jaiswal SR; Bhakuni P; Joy A; Kaushal S; Chakrabarti A; Chakrabarti S
Biol Blood Marrow Transplant; 2019 Apr; 25(4):673-682. PubMed ID: 30610925
[TBL] [Abstract][Full Text] [Related]
17. Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.
Kobayashi S; Sano H; Mochizuki K; Ohara Y; Takahashi N; Ohto H; Kikuta A
Pediatr Int; 2017 Sep; 59(9):973-978. PubMed ID: 28581032
[TBL] [Abstract][Full Text] [Related]
18. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
[TBL] [Abstract][Full Text] [Related]
19. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
20. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study.
Lin R; Wang Y; Huang F; Fan Z; Zhang S; Yang T; Xu Y; Xu N; Xuan L; Ye J; Sun J; Huang X; Liu Q
BMC Med; 2019 Aug; 17(1):156. PubMed ID: 31401973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
